PREVENTION OF RELAPSES IN SYSTEMIC LUPUS-ERYTHEMATOSUS

被引:201
作者
BOOTSMA, H
SPRONK, P
DERKSEN, R
DEBOER, G
WOLTERSDICKE, H
HERMANS, J
LIMBURG, P
GMELIGMEYLING, F
KATER, L
KALLENBERG, C
机构
[1] UNIV UTRECHT HOSP, UTRECHT, NETHERLANDS
[2] LEIDEN UNIV, DEPT MED STAT, LEIDEN, NETHERLANDS
关键词
D O I
10.1016/S0140-6736(95)90114-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Many relapses of systemic lupus erythematosus (SLE) are preceded by a rise in antibodies against double-stranded DNA (anti-dsDNA). We investigated whether these relapses can be prevented by giving prednisone when a rise in anti-dsDNA occurs. 156 patients with SLE were studied. Anti-dsDNA was measured by Farr assay monthly. When a rise in anti-dsDNA was found, patients were randomly assigned either conventional treatment or 30 mg prednisone added to the current daily dose and tapering off to baseline over 18 weeks. A rise in anti-dsDNA was detected in 46 patients (24 assigned conventional treatment and 22 prednisolone). The relapse rate was higher in the conventional group than in the prednisolone group (20 vs 2, p<0 . 001). Although rises in anti-dsDNA in the prednisone group were treated with additional prednisone, the cumulative oral doses of prednisone in the two groups did not differ significantly (p=0 . 025). 7 major relapses requiring additional cytotoxic immunosuppressive treatment occurred in the conventional group Versus 2 in the prednisone group. Treatment with prednisone as soon as a significant rise in anti-dsDNA occurs prevents relapse in most cases, without increasing the cumulative dose of prednisdone given.
引用
收藏
页码:1595 / 1599
页数:5
相关论文
共 27 条
[1]   EFFECT OF NORMALIZATION OF SERUM COMPLEMENT AND ANTI-DNA ANTIBODY ON COURSE OF LUPUS NEPHRITIS - 2 YEAR PROSPECTIVE-STUDY [J].
APPEL, AE ;
SABLAY, LB ;
GOLDEN, RA ;
BARLAND, P ;
GRAYZEL, AI ;
BANK, N .
AMERICAN JOURNAL OF MEDICINE, 1978, 64 (02) :274-283
[2]   LONG-TERM FOLLOW-UP OF PATIENTS WITH LUPUS NEPHRITIS - A STUDY BASED ON THE CLASSIFICATION OF THE WORLD-HEALTH-ORGANIZATION [J].
APPEL, GB ;
COHEN, DJ ;
PIRANI, CL ;
MELTZER, JI ;
ESTES, D .
AMERICAN JOURNAL OF MEDICINE, 1987, 83 (05) :877-885
[3]   THERAPY OF LUPUS NEPHRITIS - CONTROLLED TRIAL OF PREDNISONE AND CYTOTOXIC DRUGS [J].
AUSTIN, HA ;
KLIPPEL, JH ;
BALOW, JE ;
LERICHE, NGH ;
STEINBERG, AD ;
PLOTZ, PH ;
DECKER, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (10) :614-619
[4]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[5]   CONTROLLED TRIAL OF PULSE METHYLPREDNISOLONE VERSUS 2 REGIMENS OF PULSE CYCLOPHOSPHAMIDE IN SEVERE LUPUS NEPHRITIS [J].
BOUMPAS, DT ;
AUSTIN, HA ;
VAUGHN, EM ;
KLIPPEL, JH ;
STEINBERG, AD ;
YARBORO, CH ;
BALOW, JE .
LANCET, 1992, 340 (8822) :741-745
[6]   CORRELATION BETWEEN LEVELS OF DNA ANTIBODIES AND CLINICAL DISEASE ACTIVITY IN SLE - RETROSPECTIVE EVALUATION [J].
DAVIS, P ;
PERCY, JS ;
RUSSELL, AS .
ANNALS OF THE RHEUMATIC DISEASES, 1977, 36 (02) :157-159
[7]   IMMUNOSUPPRESSIVE DRUG-THERAPY IN LUPUS NEPHRITIS [J].
DONADIO, JV ;
GLASSOCK, RJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1993, 21 (03) :239-250
[8]   EVALUATION OF FACTORS ASSOCIATED WITH GLUCOCORTICOID-INDUCED OSTEOPENIA IN PATIENTS WITH RHEUMATIC DISEASES [J].
DYKMAN, TR ;
GLUCK, OS ;
MURPHY, WA ;
HAHN, TJ ;
HAHN, BH .
ARTHRITIS AND RHEUMATISM, 1985, 28 (04) :361-368
[9]   THE TIME-DEPENDENCE OF LONG-TERM PREDICTION IN LUPUS NEPHRITIS [J].
ESDAILE, JM ;
ABRAHAMOWICZ, M ;
MACKENZIE, T ;
HAYSLETT, JP ;
KASHGARIAN, M .
ARTHRITIS AND RHEUMATISM, 1994, 37 (03) :359-368
[10]   THE 1ST INTERNATIONAL STANDARD FOR ANTIBODIES TO DOUBLE-STRANDED DNA [J].
FELTKAMP, TEW ;
KIRKWOOD, TBL ;
MAINI, RN ;
AARDEN, LA .
ANNALS OF THE RHEUMATIC DISEASES, 1988, 47 (09) :740-746